primari
immun
thrombocytopen
purpura
itp
remain
diagnosi
exclus
nonimmun
caus
thrombocytopenia
immun
thrombocytopenia
develop
context
disord
secondari
immun
thrombocytopenia
pathobiolog
natur
histori
respons
therapi
divers
caus
secondari
itp
differ
primari
primari
immun
thrombocytopen
purpura
itp
disord
unknown
etiolog
caus
antibodi
possibl
tcell
mediat
platelet
destruct
tissu
macrophag
suppress
platelet
product
itp
remain
diagnosi
exclus
mean
exclud
nonimmun
caus
thrombocytopenia
also
condit
publish
disclaim
pdf
file
unedit
manuscript
accept
public
servic
custom
provid
earli
version
manuscript
manuscript
undergo
copyedit
typeset
review
result
proof
publish
final
citabl
form
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
tpo
receptor
cmpl
major
identifi
regul
megakaryocyt
platelet
product
also
key
role
differenti
hematopoiet
stem
cell
tpo
signal
via
cmpl
jakstat
rasrafmapk
pathway
promot
surviv
prolifer
polyploidi
megakaryocyt
vitro
studi
shown
tpo
induc
express
cmyc
protooncogen
activ
variou
physiolog
process
dysregul
megakaryocyt
product
implic
find
yet
address
vivo
stage
thrombopoiesi
includ
regul
transcript
megakaryocyt
develop
endomitot
spindl
megakaryocyt
nucleu
cytoplasm
matur
format
activ
project
propel
megakaryocyt
cytoplasm
extrus
propel
bone
marrow
stroma
circul
lastli
separ
matur
individu
platelet
extens
evid
patient
itp
develop
autoantibodi
gener
igg
bind
platelet
lead
phagocytosi
via
receptor
express
tissu
macrophag
locat
predominantli
spleen
liver
provok
autoantibodi
product
unknown
itp
patient
antibodi
integrin
glycoprotein
iiaiiib
glycoprotein
ibix
multipl
platelet
protein
time
clinic
diseas
character
thrombocytopenia
mucocutan
bleed
evid
platelet
destruct
within
macrophag
dendrit
cell
degrad
platelet
antigen
peptid
peptid
express
cell
surfac
context
mhcii
costimulatori
help
present
cell
amplifi
initi
immun
respons
possibl
gener
cryptic
epitop
platelet
glycoprotein
spread
immun
respons
involv
multipl
platelet
antigen
itp
character
reduc
tregulatori
cell
review
stasi
et
al
cytokin
lead
profil
review
hoyen
et
al
regul
costimulatori
molecul
facilit
prolifer
antigenderiv
cell
tcell
bcell
cooper
gener
isotypeswitch
high
affin
antibodi
emerg
evid
cytotox
cell
increas
bone
marrow
may
contribut
platelet
destruct
impair
product
see
import
platelet
destruct
peripheri
affirm
fact
twothird
patient
develop
maintain
remiss
splenectomi
curtail
phagocytosi
may
also
reduc
antibodi
product
time
likewis
firstand
secondlin
medic
therapi
itp
believ
work
imped
platelet
destruct
mani
year
assum
platelet
product
increas
dramat
patient
itp
compensatori
respons
thrombocytopenia
mediat
peripher
destruct
howev
becom
appar
base
studi
vivo
kinet
platelet
product
vari
mildli
increas
mildli
impair
patient
itp
synthesi
tpo
liver
regul
level
transcript
plasma
tpo
level
patient
itp
normal
minim
increas
result
increas
clearanc
hormon
bind
expand
megakaryocyt
mass
itp
antibodi
possibl
cell
inhibit
megakaryocyt
develop
vitro
may
caus
apoptosi
intramedullari
destruct
platelet
vivo
contribut
failur
splenectomi
treatment
act
inhibit
clearanc
find
also
provid
addit
rational
effect
tporeceptor
agonist
system
lupu
erythematosu
sle
antinuclear
antibodi
common
patient
itp
develop
sle
howev
patient
sle
develop
moderatesever
thrombocytopenia
readili
manag
immun
mediat
marker
sever
system
diseas
pathogenesi
thrombocytopenia
multifactori
includ
antiplatelet
glycoprotein
antibodi
found
itp
immun
complex
divers
composit
antiphospholipid
antibodi
apla
see
vascul
thrombot
microangiopathi
hemophagocytosi
autoantibodi
cmpl
receptor
megakaryocyt
bone
marrow
stromal
alter
characterist
itp
therefor
thorough
clinic
laboratori
assess
often
requir
diagnosi
secondari
immun
thrombocytopenia
entertain
also
import
limit
use
corticosteroid
cytotox
agent
often
heavili
treat
patient
splenectomi
may
provid
transient
benefit
reserv
patient
sever
thrombocytopenia
predomin
reason
treatment
antiphospholpid
syndrom
ap
antiphospholipid
apla
antibodi
lupu
inhibitor
bind
anion
phospholipid
prothrombin
among
specif
found
patient
itp
depend
thorough
search
signific
debat
patient
develop
ap
presenc
apla
per
se
influenc
effect
itp
therapi
term
induc
platelet
respons
howev
studi
suggest
patient
may
risk
thrombosi
respond
diagnosi
complic
fact
approxim
patient
ap
develop
mildmoder
thrombocytopenia
sever
thrombocytopenia
ap
correl
close
presenc
antiplatelet
glycoprotein
antibodi
either
apla
clinic
manifest
howev
platelet
express
receptor
theori
could
lead
aplamedi
platelet
activ
alon
associ
agonist
anecdot
report
respons
aspirin
perhap
inhibit
coagulationmedi
platelet
consumpt
thyroid
diseasemildmoder
thrombocytopenia
found
commonli
patient
hyperthyroid
platelet
surviv
reduc
return
normal
restor
euthyroid
state
similarli
mild
thrombocytopenia
respons
hormon
replac
also
occur
patient
hypothyroid
possibl
due
impair
product
howev
patient
immun
thyroid
diseas
develop
immun
thrombocytopenia
requir
itpdirect
therapi
commonli
attribut
chanc
moreov
antithyroid
antibodi
occur
commonli
adult
children
itp
lead
recommend
test
thyroid
function
nonrespons
patient
prior
splenectomi
evan
syndrom
es
patient
es
develop
immun
hemolyt
anemia
immun
thrombocytopenia
occasion
immun
neutropenia
remark
coincid
two
three
seemingli
unrel
hematopoiet
cell
antibodi
associ
underli
complex
immunodefici
patient
see
hemolysi
may
preced
follow
onset
thrombocytopenia
typic
refractori
intervent
two
cytopenia
often
dyssynchron
manifest
respons
rate
itpdirect
therapi
includ
splenectomi
less
primari
diseas
children
adult
es
clinic
patholog
present
overlap
autoimmun
lymphoprolif
syndrom
alp
alp
character
chronic
accumul
nonmalign
lymphocyt
lead
lymphadenopathi
hepato
splenomegali
doubl
neg
cell
impair
fasreceptorligand
mediat
apoptosi
vitro
due
mutat
fa
less
commonli
fa
ligand
fasl
immun
thrombocytopenia
develop
patient
may
respond
rel
poorli
itp
therapi
although
recent
experi
rituximab
mycophenyl
encourag
immun
thrombocytopenia
es
also
occur
approxim
patient
common
variabl
hypogammaglobulinemia
onset
immun
thrombocytopenia
typic
third
decad
though
onset
childhood
old
age
report
typic
preced
diagnosi
common
variabl
immun
defici
cvid
sever
year
diagnosi
sought
patient
recurr
infect
immunosuppress
therapi
pose
risk
replac
immun
globulin
indic
increas
incid
immun
thrombocytopenia
patient
chronic
lymphocyt
leukemia
cll
tlymphocyt
larg
granular
lymphocyt
leukemia
lgl
possibl
hodgkin
diseas
cll
may
difficult
distinguish
immun
thrombocytopenia
marrow
infiltr
splenomegali
set
treatment
fludarabin
sever
thrombocytopenia
occur
patient
lgl
associ
clonal
suppress
megakaryopoiesi
human
immunodefici
virusth
associ
immun
thrombocytopenia
acquir
immunodefici
syndrom
subsequ
present
featur
hiv
infect
recogn
sinc
earli
mid
thrombocytopenia
character
immun
compon
similar
present
respons
itp
evid
earli
stage
diseas
progress
ineffect
hematopoiesi
decreas
platelet
product
result
megakaryocyt
infect
marrow
infiltr
diseas
progress
hiv
bind
receptor
coreceptor
express
megakaryocyt
intern
replic
within
infect
cell
lead
dysplasia
bleb
surfac
membran
vacuol
peripher
cytoplasm
immun
compon
mediat
molecular
mimicri
involv
antihiv
antibodi
crossreact
plateletmembran
glycoprotein
immun
complex
antibodi
induc
platelet
lysi
least
vitro
peroxidasemedi
pathway
secondari
caus
thrombocytopenia
hiv
infect
gener
result
underli
opportunist
infect
malign
medic
eg
chemotherapeut
agent
interferon
antivir
agent
less
frequent
thrombot
microangiopathi
hiv
exclud
atrisk
patient
present
itp
patient
present
immun
thrombocytopenia
earli
cours
hiv
infect
respond
medic
therapi
corticosteroid
iv
antid
ivig
splenectomi
well
patient
itp
without
prolifer
hiv
infect
untoward
incid
opportunist
infect
thrombocytopenia
patient
advanc
diseas
gener
respond
highli
activ
antiretrovir
therapi
helicobact
pylori
h
pylori
success
erad
infect
h
pylori
among
patient
present
otherwis
typic
itp
vari
less
us
itali
japan
intermedi
valu
report
countri
sever
hypothes
relat
h
pylori
immun
thrombocytopenia
explain
variat
propos
includ
region
differ
express
cagarel
gene
antibodi
crossreact
itp
platelet
gener
process
molecular
mimicri
crossreact
platelet
antibodi
h
pylori
cytotoxina
protein
adsorpt
platelet
lewi
antigen
induc
h
pylori
strainspecif
manner
target
antilewi
antibodi
patient
appropri
genet
background
platelet
activ
clearanc
interact
h
pyloribound
von
willebrand
factor
via
platelet
glycoprotein
ib
somat
mutat
antibacteri
antibodi
antigenindepend
autoantibodi
emerg
monocyt
h
pyloriposit
patient
demonstr
low
level
inhibitori
receptor
iib
enhanc
platelet
phagocytosi
revers
success
erad
genet
variat
eg
frequenc
hladrb
higher
patient
immun
thrombocytopenia
posit
h
pylori
h
pylorineg
express
higher
probabl
platelet
respons
erad
therapi
interest
titer
autoantibodi
fall
week
success
erad
wherea
respons
often
occur
week
suggest
addit
mechan
oper
mani
studi
indic
h
pylori
found
commonli
patient
diseas
milder
sever
recent
onset
thu
h
pylori
sought
patient
come
region
strong
associ
consensu
emerg
us
whether
itp
patient
test
andor
treat
vaccin
infectionstransi
sever
thrombocytopenia
occur
incid
vaccin
measl
mump
rubella
less
commonli
vaccin
pneumococcu
h
influenza
b
varicella
zoster
viru
vzv
hepat
b
patient
recov
within
month
typic
within
week
less
evolv
chronic
itp
respons
itpdirect
therapi
thrombocytopenia
occur
occasion
natur
occur
infect
cytomegaloviru
rubella
epsteinbarr
viru
vzv
sever
acut
respiratori
syndrom
coronaviru
mani
other
thrombocytopenia
may
immun
due
infect
megakaryocyt
progenitor
result
peripher
consumpt
eg
purpura
fulminan
due
vzv
ptp
rare
dramat
caus
immun
thrombocytopenia
typic
patient
multipar
multitransfus
femal
present
hemorrhag
sudden
onset
profound
thrombocytopenia
mean
day
transfus
blood
product
contain
platelet
antigen
diseas
occur
primarili
among
caucasian
homozyg
allel
gpiiia
although
specif
report
patient
develop
antibodi
also
selfreact
antibodi
undetermin
specif
presum
result
epitop
spread
remark
ptp
seen
women
neonat
alloimmun
thrombocytopenia
due
antibodi
patient
high
risk
bleed
clinic
cours
often
protract
without
therapi
iv
immun
globulin
standard
care
util
prevent
subsequ
exposur
incit
antigen
use
wash
blood
product
logic
unproven
first
case
druginduc
thrombocytopenia
ditp
identifi
quinin
year
ago
ditp
result
bone
marrow
toxic
immunemedi
destruct
platelet
sever
hundr
therapeut
agent
implic
report
compel
diagnosi
ditp
gener
base
clinic
scenario
therapi
candid
drug
preced
thrombocytopenia
suffici
time
develop
antibodi
tempor
relationship
anoth
drug
reason
caus
exclud
recoveri
occur
upon
discontinu
drug
reexposur
drug
attempt
lead
recurr
thrombocytopenia
howev
criteria
rare
met
underli
clinic
circumst
often
complex
introduct
withdraw
multipl
drug
within
short
time
frame
common
moreov
test
drugdepend
antibodi
fraught
difficulti
solubl
concentr
effect
platelet
activ
vivo
metabol
lack
control
patient
drug
without
thrombocytopenia
etc
patient
requir
rechalleng
ditp
typic
affect
small
percentag
expos
patient
except
heparininduc
thrombocytopenia
see
known
genet
predisposit
environment
criteria
identifi
divers
mechan
postul
caus
ditp
includ
immun
complex
heparin
induct
autoantibodi
gold
salt
antidrugspecif
antibodi
abciximab
drug
induc
conform
chang
platelet
antigen
recogn
antibodi
fiban
drug
druginduc
antibodi
bind
platelet
membran
presenc
solubl
drug
quinin
haptendepend
antibodi
betalactam
antibiot
tabl
immun
nonimmun
marrow
suppress
nonimmun
destruct
typifi
ristocetin
introduc
antibiot
thrombot
microangiopathi
eg
ticlopidin
possibl
clopidogrel
occur
less
commonli
surprisingli
drugdepend
antibodi
appear
recogn
antigen
involv
preval
platelet
glycoprotein
complex
ibvix
hypothes
drug
becom
immunogen
bind
larger
molecul
protein
gener
antibodi
drug
drugprotein
complex
druginduc
alter
bind
protein
induc
neoepitop
hypothes
base
primarili
kinet
drugdepend
inhibit
antibodi
bind
platelet
cell
rather
isol
drugprotein
drugantibodi
drugproteinantibodi
complex
bougi
colleagu
propos
model
reconcil
exist
hypothes
use
quininedepend
antibodi
model
posit
drug
enhanc
affin
preexist
antiplatelet
glycoprotein
antibodi
provid
bridg
complement
determin
region
former
drugbind
epitop
latter
whether
drug
bind
first
antibodi
platelet
membran
protein
depend
rel
affin
thrombocytopenia
induc
platelet
inhibitorstirofiban
eptifibatid
use
prevent
restenosi
coronari
angioplasti
caus
sever
thrombocytopenia
within
hour
first
subsequ
dose
ligandmimet
drug
fiban
competit
inhibit
fibrinogen
bind
platelet
integrin
receptor
drug
may
act
mix
agonistsantagonist
presum
bind
induc
novel
epitop
recogn
preexist
possibl
preactiv
druginduc
antibodi
abciximab
chimer
antibodi
human
fab
fragment
link
specificitydetermin
sequenc
murin
antibodi
integrin
block
fibrinogen
bind
sudden
often
profound
thrombocytopenia
develop
within
hour
patient
treat
abciximab
first
time
treat
second
time
delay
onset
first
exposur
occur
less
commonli
healthi
individu
naturallyoccur
antibodi
cterminu
human
fab
papain
cleavag
site
present
chimer
antibodi
contrast
patient
develop
sever
thrombocytopenia
within
hour
start
infus
preexist
antibodi
recogn
region
impart
gpiiia
specif
although
effect
drug
conform
gpiibiiia
exclud
abciximabco
platelet
may
detect
day
treatment
individu
presum
due
coat
megakaryocyt
shuttl
destroy
circul
platelet
ivig
platelet
transfus
use
success
treat
patient
profound
abciximaband
fibaninduc
thrombocytopenia
thrombocytopenia
druginduc
autoantibodiesrar
drug
stimul
format
autoantibodi
target
platelet
absenc
incit
drug
autoantibodi
affin
platelet
glycoprotein
v
develop
patient
rheumatoid
arthriti
treat
gold
salt
drugindepend
autoantibodi
also
report
occasion
patient
treat
quinin
procainamid
sulfonamid
antibiot
interferon
alfa
beta
thrombocytopenia
often
protract
may
requir
itpdirect
therapi
heparininduc
thrombocytopeniaheparininduc
thrombocytopenia
hit
develop
patient
receiv
unfraction
heparin
ufh
intraven
therapeut
dose
minimum
day
preval
lower
patient
treat
exclus
lowmolecularweight
heparin
ufh
given
thromboprophylaxi
incid
highest
patient
undergo
cardiopulmonari
bypass
surgeri
associ
intens
platelet
activ
inflamm
underli
vascular
diseas
lowest
children
pregnanc
patient
receiv
heparin
dialysi
approxim
patient
develop
arteri
andor
venou
thrombi
number
may
exceed
diseas
recogn
manag
promptli
subject
unexplain
fall
platelet
count
greater
begin
day
exposur
thrombosi
typic
follow
soon
occur
concomitantli
occas
preced
fall
platelet
count
thrombocytopenia
may
occur
within
hour
exposur
heparin
patient
treat
within
preced
day
circul
antibodi
may
persist
rare
thrombocytopenia
may
discov
develop
week
last
known
exposur
delay
hit
hit
antibodi
recogn
oligomer
complex
form
platelet
factor
releas
activ
platelet
heparin
glycosaminoglycan
express
endothelium
monocyt
platelet
complex
bind
platelet
target
clearanc
also
stimul
cell
activ
releas
addit
bind
complex
endotheli
cell
monocyt
stimul
express
tissu
factor
acceler
coagul
reinforc
platelet
activ
heparinindepend
antibodi
postul
account
delay
hit
diagnosi
rest
clinic
recognit
tempor
relationship
heparin
exposur
signatur
clinic
manifest
elisabas
assay
detect
igg
iga
igm
antibodi
high
sensit
neg
predict
valu
fals
posit
rate
exceed
patient
postbypass
surgeri
unaccept
high
fals
posit
rate
set
well
perform
characterist
may
improv
use
newer
assay
measur
igg
antibodi
use
higher
diagnost
cutoff
optic
densiti
measur
littl
loss
neg
predict
valu
assay
base
platelet
activ
specif
less
sensit
result
routin
avail
realtim
diagnosi
strongli
suspect
moderatehigh
pretest
probabl
exposur
form
heparin
includ
flush
heparinbond
cathet
etc
must
discontinu
anticoagul
begun
either
direct
thrombin
inhibitor
hirudin
argatroban
antixa
agent
danaparoid
avail
therapi
reduc
new
thromboembol
event
approxim
twothird
mortal
rate
amput
due
preexist
clot
affect
therapi
continu
thrombocytopenia
resolv
overlap
coumadin
therapeut
intern
normal
ratio
inr
day
anticoagul
gener
continu
month
may
extend
depend
underli
reason
initi
use
heparin
sequela
hitinduc
thrombosi
compel
reason
diagnosi
itp
requir
exclus
caus
thrombocytopenia
includ
condit
classifi
secondari
immun
thrombocytopenia
pathobiolog
variou
caus
secondari
immun
thrombocytopenia
often
complex
itp
eg
marrow
suppress
intravascular
consumpt
due
clot
vascular
damag
differ
natur
histori
respons
itpdirect
therapi
eg
evan
syndrom
optim
therapi
requir
treatment
underli
condit
eg
chronic
infect
lymphoprolif
diseas
cll
lgl
autoimmun
condit
eg
sle
ap
treatment
h
pylori
hiv
hcv
may
suffic
increas
platelet
count
avoid
protract
sometim
ineffect
toxic
treatment
requir
manag
itp
druginduc
thrombocytopenia
requir
recognit
withdraw
incit
agent
posttransfus
purpura
requir
immedi
recognit
treatment
ivig
patient
ap
may
risk
thrombosi
treatment
strategi
form
immun
thrombocytopenia
discuss
greater
detail
elsewher
issu
semin
hematol
author
manuscript
avail
pmc
januari
